Brand dynamics

Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health

Real-world data from multiple countries shows that sequential strengthening with V-01 may be one of the best combinations for global epidemic prevention and control.

Published Time:

2022-03-31

  Real-world data from multiple countries shows that booster shots significantly improve the absolute protective efficacy against Omicron. Data on the sequential booster of V-01 from China's CSPC Pharmaceutical Group is also quite impressive, enough to place it among the top-tier international COVID-19 vaccines.

 

Zhuhai CSPC Antibody Biotechnology Co., Ltd. (“CSPC Antibody”), a subsidiary of CSPC Pharmaceutical Group (000513.SZ), and the Institute of Biophysics, Chinese Academy of Sciences, have jointly developed a "recombinant novel coronavirus fusion protein vaccine" (referred to as "V-01"), which has completed the interim primary data analysis of its sequential booster Phase III clinical trial and obtained key data.

 

Data shows that the CSPC V-01 vaccine, the world's first COVID-19 vaccine to achieve protective efficacy against prevalent strains including Omicron, has an absolute protective efficacy of 61.35%, and 71.83% for people with underlying diseases, meeting WHO effectiveness standards and comparable to mRNA booster protection. A two-dose inactivated vaccine followed by a V-01 booster may become the optimal combination for safe and effective protection against Omicron and other variants.

 

Entering the First Tier of International Vaccines Compared with Real-World Data Disclosed in Publications Such as the New England Journal of Medicine

Real-world data refers to data from real-world medical settings, outside of traditional clinical trials, reflecting the health status and medical service processes of patients in actual clinical practice. Research using real-world data to address relevant scientific questions, integrating epidemiological, biostatistical, and evidence-based medicine methods and techniques, is collectively known as real-world research.

 

Some believe that real-world studies (RWS) are the best approach to clinical research in the 21st century. It will replace "RCT" as the primary method of clinical research.

 

An article published in The New England Journal of Medicine on March 9, 2022, shows that researchers conducted two matched retrospective cohort studies. Real-world research results from Qatar show that the relative protection against symptomatic Omicron infection for a third Pfizer booster dose after two doses of Pfizer vaccine was 49.4% (95%CI: 47.1~51.6); for a third Moderna booster dose after two doses of Moderna vaccine, the relative protection was 47.3% (95%CI: 40.7~53.3).

 

According to the results of CSPC Group's disclosed Phase III clinical trial of V-01, with a sequential V-01 booster 3-6 months after two doses of inactivated vaccine, the relative protection was 47.8%. The protective efficacy is comparable to homologous mRNA immunization.

 

Real-world data from the UK, also published in The New England Journal of Medicine, shows that among subjects who received an adenovirus vaccine (AstraZeneca) as a primary immunization, the absolute protective efficacy was 62.4% (95%CI: 61.8~63.0) two to four weeks after a booster dose of mRNA vaccine (Pfizer). An article published in Nature Medicine, using real-world data from the United States, shows that the absolute protective efficacy of three doses of mRNA-1273 (Moderna) against Omicron infection was 62.5% (56.2%-67.9%).

 

Randomized, double-blind Phase III data from Pakistan and Malaysia show that the absolute protective efficacy of V-01 after sequential boosting is 61.35%, demonstrating significantly superior efficacy and meeting WHO standards. Furthermore, group studies of high-risk populations show that the protection rate for high-risk individuals with underlying diseases is 71.83%, including 61.19% for those over 60 or with underlying diseases. Clearly, a sequential V-01 booster 3-6 months after two doses of inactivated vaccine provides absolute protection comparable to mRNA booster immunization.

 

Compared using real-world data, the protection provided by a sequential V-01 booster after two doses of inactivated vaccine is comparable to homologous mRNA immunization and mRNA booster immunization. With such impressive data, CSPC V-01 is poised to enter the top tier of international vaccines.

 

Working Towards Global Booster Immunization CSPC V-01 Greatly Reduces the Risk of Severe Illness in Elderly Patients with Underlying Diseases

V-01, initiated in July 2020, is an innovative, independently developed recombinant protein COVID-19 vaccine jointly developed by CSPC Antibody and the Institute of Biophysics, Chinese Academy of Sciences.

 

Recently, Fudan University published an important study in BMC Medicine, evaluating the long-term neutralizing antibody kinetics and predicting their protection and immunity levels based on the neutralizing antibody data of several vaccines. Based on the actual efficacy data of the sequential booster study 28-84 days, using the CSPC vaccine as a booster after two doses of inactivated vaccine effectively combats Omicron infection.

 

Data shows that CSPC V-01 as a booster shot has good sequential booster immunization effects: Results from multiple domestic and international sequential immunization clinical studies of V-01 show that V-01, when used as a booster shot, can rapidly and significantly increase neutralizing antibody titers, effectively combating multiple variants, and exhibiting strong neutralizing activity against the Omicron variant, comparable to the wild-type neutralizing activity; high-titer neutralizing antibodies are maintained for a long time, and the booster immunization effect in the elderly population is no lower than that in the adult group.

 

Preliminary analysis of clustered outbreaks in multiple locations in China this year shows that the risk of severe illness in vaccinated elderly people is significantly lower than in unvaccinated elderly people. However, data on cumulative reported COVID-19 vaccine vaccinations in China shows that as of February 25, approximately 220 million people aged 60 and over have received vaccination coverage, and approximately 211 million have completed the full course of vaccination. The vaccination rate for people aged 60 and over, especially those aged 80 and over, remains low. Increasing the vaccination rate among the elderly is of great significance in reducing the mortality rate of COVID-19.

 

Currently, the full vaccination rate in China exceeds 87%, but only 30% of people over 60 have received booster shots. Over 2 billion doses of inactivated vaccines have been exported to more than 120 countries worldwide, and all currently face the need for a third booster shot. The booster shot rate will help China and the world build a herd immunity barrier. The two-dose inactivated vaccine followed by a V-01 booster is both uniquely Chinese and features China's independent intellectual property. Studies show that this combination can safely and effectively combat Omicron and other variants, especially for high-risk groups such as the elderly and those with underlying diseases. The imminent launch of CSPC V-01 will not only support continued booster immunization in China but will also provide more flexible and scientific options for global booster immunization. While fully demonstrating China's R&D capabilities, it also reflects the responsibility of Chinese pharmaceutical companies, such as CSPC Pharmaceutical Group, making a Chinese contribution to the accessibility and affordability of vaccines globally, especially in developing countries.

 

CSPC Pharmaceutical Group stated that it is actively promoting the conditional marketing application for this vaccine.

 

Source: Securities Market Red Weekly